| Project/Area Number |
01480188
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | KYOTO UNIVERSITY |
|---|
Principal Investigator |
YODOI Junji Kyoto Univ., Virces Research Inst., Professor, ウィルス研究所 (80108993)
|
|---|
| Project Period (FY) |
1989 – 1990
|
| Project Status |
Completed (Fiscal Year 1990)
|
| Budget Amount *help |
¥6,000,000 (Direct Cost: ¥6,000,000)
Fiscal Year 1990: ¥2,400,000 (Direct Cost: ¥2,400,000)
Fiscal Year 1989: ¥3,600,000 (Direct Cost: ¥3,600,000)
|
|---|
| Keywords | FcepsilonRII / CD23 / Tyrosine Kinase / Epstein-Barr Virus / Rheumatoid Arthritis / FcεRII / IδE結合因子 / In Situ Hybridization / エンハンサ- / IL-4 |
|---|
| Research Abstract |
We had established and cloned a monoclonal antibody and a cDNA for human Fc receptor for IgE, before. This time we found new regulatory factors of FcepsilonRII/CD23 such as TGF-beta or Platelate Activating Factor (PAF). We also confirmed the production of FcepsilonRII/CD23 by normal human T lymphocytes (J. Immunol. in press) and revealed some of the mechanisms of it which had been a controversial problem in this field. Since the expression of FcepsilonRII/CD23 was highly augmented in the process of EBV transformation of B lymphocytes, the mechanisms of the signal transduction through this receptor attracts many scientists. Recently we found a association of a tyrosine kinase (fyn) with this receptor in the stable transfectant of it (YTSER) (Proc. Natl. Acad. Sci., USA in press), and the other association with the other tyrosine kinase and this receptor in B lymphocytes. We will analyse the molecular character of this tyrosine kinase. On the other hand, the establishment of the detection systems of soluble FcepsilonRII/CD23 (sCD23) by sandwich ELISA method revealed that the serum levels of sCD23 was elevated in the patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematodes (SLE). To study the biological significance and especially the mechanisms of the high levels of existence of sCD23 in these patients, we are producing recombinant 25kD sCD23 in collaboration with Midori Juji CO. We will continue to study the biological functions of this receptor and its soluble forms.
|
